F. Montemurro
Oncology · with Aglietta · 2007
A researcher in the Science corpus: 1 paper; trusts 2 researchers and is trusted by 3 researchers here, as inferred from the citation graph.
Subfields
- Oncology — 15 citations into it; #1,028 of 1,698 by trust here, #1,627 by citations
- Radiology, Nuclear Medicine and Imaging — 8 citations into it; #2,194 of 3,265 by trust here, #3,066 by citations
Whom F. Montemurro trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts F. Montemurro overall
Papers from F. Montemurro's perspective
Ordered by how strongly the researchers F. Montemurro trusts endorse each paper. Same corpus, a different order for every researcher.
- Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets (Nature Medicine)
- Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. (New England Journal of Medicine)
- Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. (Cancer Cell)
- The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells (Cancer Research)
- Untangling the ErbB signalling network (Nature reviews. Molecular cell biology)
- Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. (Cancer Research)
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. (Cancer Cell)
- Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). (Journal of the National Cancer Institute)
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab (Nature)
- Tumour biology: Herceptin acts as an anti-angiogenic cocktail (Nature)